Skip to main content
OpenTrials
Completed

NCT Number: NCT03932240

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

This primary aim of this study is to compare the in vivo effects of fibrinogen concentrate and cryoprecipitate on the neonatal fibrin network after surgery with cardiopulmonary bypass to develop effective and safe strategies for managing coagulopathies in neonates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

1 day–30 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Children's Healthcare of Atlanta (CHOA), Egleston

Atlanta, Georgia, 30322, United States

About this study

This study is a prospective, randomized control trial comparing two different sources of fibrinogen on clot kinetics (degradation and structure) in post-CPB coagulopathy in neonates undergoing cardiac surgery. The two sources of fibrinogen include the blood product, cryoprecipitate, and a blood product alternative, fibrinogen concentrate. Cryoprecipitate is an allogenic blood product that requires cross-matching and thawing prior to administration and is associated with immunologic reactions and possible pathogen transmission. Fibrinogen concentrate, a blood product alternative, is a purified form of fibrinogen, which undergoes a pasteurization process to minimize the risk of immunologic and allergic reactions. The primary aim of this study is compare the in vivo effect of post-CPB administration of FC, a blood product alternative, to cryoprecipitate on neonatal clot properties and clinical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Full term neonates (36-42 weeks gestational age)
  • Infants =< 30 days of age at time of surgery
  • APGAR score of 6 or greater at 5 minutes after delivery
  • Neonates undergoing elective cardiac surgery requiring CPB at Children's Healthcare of Atlanta
  • Parents willing to participate and able to understand and sign the provided informed consent

Exclusion criteria

  • Preterm neonates (less than 36 weeks gestation)
  • Patients undergoing an emergent procedure or surgery not requiring CPB
  • Patients with personal or family history of a coagulation defect or coagulopathy
  • Parents unwilling to participate or unable to understand and sign the provided informed consent

Treatment and study plan

Fibrinogen Concentrate (FC)

Drug

The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.

Other names: RiaSTAP

Cryoprecipitate

Drug

The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.

Primary outcomes

  1. Clot Degradation at 24 Hours Post-operatively

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples were obtained from an arterial line that was required for the planned surgical procedure. Samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Clot degradation was determined by degradation kinetic study. Blood samples were collected at four time points:1) baseline sample within 24 hours of surgery and after induction of anesthesia prior to CPB; 2) after termination of CPB and transfusion of platelets and either cryoprecipitate or fibrinogen (within 1 hour of separation from bypass; 3) upon arrival to the ICU; 4) 24 hours post-operatively. The primary outcome is to examine differences in clot degradation between study arms at 24 hours post-surgery.

Secondary outcomes

  1. Clot Strength

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples will be obtained from an arterial line that is required for the planned surgical procedure. They will be centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Strength will be assessed by rheology and atomic force microscopy (AFM).

  2. Clot Polymerization Kinetic

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples will be obtained from an arterial line that is required for the planned surgical procedure. They will be centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. Polymerization will be determined by thrombin-initiated turbidity/absorbency curves.

  3. Fibrin Fiber Alignment

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Clot structure is assessed by examination of images of clot fibrin fiber alignment. Quantification of clot fiber alignment was achieved through the application of an automated algorithm based on a fast Fourier transform that measures the alignment of the fibers, as well as visual inspection. A reference range has not been established for neonates, however, higher values indicate more dense clot structure.

  4. Interoperative Transfusion Requirement

    Time frame: During surgery (up to 6 hours)

    Blood product transfusion requirements were obtained from electronic medical records. An increased transfusion requirement indicates increased interoperative bleeding, thus, lower values are preferable.

  5. Transfusion Requirements Within the First 24 Hours After Surgery

    Time frame: 24 hours postoperatively

    Transfusion requirements within the first 24 hours of surgery were obtained from electronic medical records.

  6. Amount of Post-operative Bleeding

    Time frame: Up to 24 hours postoperatively

    Post-operative bleeding was recorded by 24 hour chest tube output. Higher values indicate greater post-operative bleeding.

  7. Mechanical Ventilation Time

    Time frame: Time of extubation (up to 2 weeks)

    Mechanical ventilation time was obtained from medical records. Higher values indicate increased need for mechanical ventilation.

  8. Length of ICU Stay

    Time frame: At discharge from ICU (typically up to 21 days)

    Length of ICU stay was obtained from medical records. A shorter ICU stay indicates a favorable state of health.

  9. Length of Hospital Stay

    Time frame: At discharge from hospital (up to 150 days)

    Length of hospital stay was obtained from medical records. A shorter hospital stay indicates a favorable state of health.

  10. Number of Adverse Events

    Time frame: Within seven days of surgery

    Adverse events within seven days of surgery were obtained from medical records.

Other outcomes

  1. Number of Events of Postoperative Thrombosis

    Time frame: Within the first 24 hours of surgery

    The number of events of clinically significant postoperative thrombosis that required treatment were obtained from medical records.

  2. Fibrinogen Plasma Level

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. Normal fibrinogen plasma values are between 0.5 to 15 mcg/mL.

  3. Thrombin Plasma Level

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. The reference range for thrombin plasma level is 0.000313 to 0.02 mcg/mL.

  4. FXIII Plasma Level

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. The reference range for FXIII plasma level is 0.000469 to 0.03 mcg/mL.

  5. Von Willebrand Factor Plasma Level

    Time frame: From induction of anesthesia to 24 hours postoperatively

    Blood samples were obtained from an arterial line that was required for the planned surgical procedure. The samples were centrifuged to yield platelet poor plasma (PPP), stored at -80 degrees Celsius and utilized for the clot analysis. ELISA was used to measure coagulation factors at each time point. Lower values may indicate an increased risk of excessive bleeding.

Sponsors and collaborators

Lead sponsor

Emory University

Other

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Apr 30, 2019
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.